2024
VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, Harris T, Hunt B, Fass R, Katz P. VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL. Clinical Gastroenterology And Hepatology 2024 PMID: 38750866, DOI: 10.1016/j.cgh.2024.05.004.Peer-Reviewed Original ResearchNon-erosive reflux diseaseHeartburn-free daysErosive esophagitisReflux diseaseRandomized trialsActive-treatment extensionRandomized to placeboPotassium-competitive acid blockerPlacebo-controlled periodDays of therapyPercentage of subjectsPrimary endpointPercentage of daysHeartburn symptomsPlaceboVonoprazanAcid blockerNighttime heartburnDay 1Randomized subjectsDocumented efficacyStudy armsDay 2Adult subjectsExtension period
2008
Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials
Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G, Cohard-Radice M. Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. The American Journal Of Gastroenterology 2008, 103: ajg2008383. PMID: 18616658, DOI: 10.1111/j.1572-0241.2008.01953.x.Peer-Reviewed Original ResearchConceptsDysmotility-like functional dyspepsiaFunctional dyspepsiaSatisfactory symptom reliefTegaserod treatmentSymptom reliefDaily severity scoresPlacebo-controlled trialSevere baseline symptomsHelicobacter pylori statusTrial 2Trial 1Percentage of daysEarly satietyIdentical multicenterPostprandial fullnessStudy discontinuationAbdominal discomfortControlled TrialsMedication usePylori statusSeverity scoreReceptor agonistBaseline symptomsTegaserodClinical implications